Protara Therapeutics, Inc. (TARA) Stock Score, Valuation & Financial Research

Protara Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TARA

Protara Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.56. These figures are a research snapshot, not a buy or sell recommendation.

What Protara Therapeutics, Inc. does

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Protara Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research, development, and clinical advancement of transformative therapies for cancer and rare diseases, funded primarily through capital raises and equity financing.

Products and services

  • The company's primary product candidate is TARA-002, an investigational cell-based therapy currently in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs).

Brands and product families

  • TARA-002 — Lead investigational cell-based therapy candidate. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting significant unmet medical needs Source
  • FDA Breakthrough Therapy Designation for TARA-002 Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, TARA-002 Source
  • Risks associated with clinical trial delays, failures, or regulatory rejection Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TARA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.56
Market capitalization:
143.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -70.02M
Free cash flow:
USD -56.46M
Cash:
USD 17.08M
Total debt:
USD 2.75M
EPS:
USD -1.36

What stands out

  • Free cash flow is USD -56.46M, negative for the stored period.
  • The balance sheet shows USD 17.08M of cash versus USD 2.75M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 14.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TARA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TARA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TARA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TARA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TARA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TARA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.